Concomitant myeloproliferative and lymphoproliferative neoplasms, distinct progenitors: A case report and review of the literature

Mousinho,Filipa; Santos,Paula  Sousa E.; Azevedo,Ana  P.; Pereira,José  Manuel; Lemos,Raquel; Matos,Sónia; Viana,João  Faro; Lima,Fernando

doi:10.3892/mco.2018.1682

Concomitant myeloproliferative and lymphoproliferative neoplasms, distinct progenitors: A case report and review of the literature

Authors:
- Filipa Mousinho
- Paula Sousa E. Santos
- Ana P. Azevedo
- José Manuel Pereira
- Raquel Lemos
- Sónia Matos
- João Faro Viana
- Fernando Lima
View Affiliations

Affiliations: Clinical Hematology Department, Hospital of São Francisco Xavier, West Lisbon Hospital Centre, 1449‑005 Lisbon, Portugal, Clinical Pathology Department, Hematology Laboratory, Hospital of São Francisco Xavier, West Lisbon Hospital Centre, 1449‑005 Lisbon, Portugal, Clinical Pathology Department, Flow Cytometry Laboratory, Hospital of São Francisco Xavier, West Lisbon Hospital Centre, 1449‑005 Lisbon, Portugal, CGC Genetics, 4000‑432 Porto, Portugal, GenoMed‑Molecular Medicine Diagnosis, Molecular Medicine Institute, Faculty of Medicine University of Lisbon, 1649‑028 Lisbon, Portugal
Published online on: July 19, 2018 https://doi.org/10.3892/mco.2018.1682
Pages: 347-349

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Patients with a Philadelphia chromosome-negative myeloproliferative neoplasm may develop a lymphoproliferative disorder; however, the clinical and molecular determinants and the chronological onset of the two events remain unknown. We herein report the case of a 64‑year‑old man with concomitant diagnosis of high‑risk essential thrombocythemia with evidence of a thrombotic event and high‑count monoclonal B‑cell lymphocytosis (high‑count MBL). The patient harbored a JAK2V617F mutation and one of the most common genetic alterations found in chronic lymphocytic leukemia (CLL) (del 13q), which may represent a sign of disease progression. He was initiated on cytoreductive therapy with hydroxyurea 500 mg 3 times per week and hypocoagulation treatment, and is currently under regular surveillance of MBL without CLL criteria.

View Figures

View References

1	Marchetti M, Carobbio A, Capitoni E and Barbui T: Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: A systematic review. Am J Hematol. 93:698–703. 2018. View Article : Google Scholar : PubMed/NCBI
2	Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD and Jaffe ES: The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 127:2375–2390. 2016. View Article : Google Scholar : PubMed/NCBI
3	Strati P and Shanafelt TD: Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: Diagnosis, natural history and risk stratification. Blood. 126:454–462. 2015. View Article : Google Scholar : PubMed/NCBI
4	Duarte S, Pereira SC, Rodrigues É and Pereira A: Concomitant chronic myeloid leukemia and monoclonal B cell lymphocytosis-a very rare condition. Rev Bras Hematol Hemoter. 39:167–169. 2017. View Article : Google Scholar : PubMed/NCBI
5	Herishanu Y, Pérez-Galán P, Liu D, Biancotto A, Pittaluga S, Vire B, Gibellini F, Njuguna N, Lee E, Stennett L, et al: The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation and tumor proliferation in chronic lymphocytic leukemia. Blood. 117:563–574. 2011. View Article : Google Scholar : PubMed/NCBI
6	Shanafelt TD, Byrd JC, Call TG, Zent CS and Kay NE: Narrative review: Initial management of newly diagnosed, early-stage chronic lymphocytic leukemia. Ann Intern Med. 145:435–447. 2006. View Article : Google Scholar : PubMed/NCBI
7	Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, Score J, Seear R, Chase AJ, Grand FH, et al: Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 106:2162–2168. 2005. View Article : Google Scholar : PubMed/NCBI
8	Hauck G, Jonigk D, Kreipe H and Hussein K: Simultaneous and sequential concurrent myeloproliferative and lymphoproliferative neoplasms. Acta Haematol. 129:187–196. 2013. View Article : Google Scholar : PubMed/NCBI
9	Trifa AP, Cucuianu A, Popp RA, Paţiu M, Selicean C, Militaru MS and Pop IV: Concomitant myeloproliferative and lymphoid neoplasms in two patients positive for JAK2 V617F mutation. Case report and literature review. Indian J Hematol Blood Transfus. 30 Suppl 1:S120–S123. 2014. View Article : Google Scholar
10	Kodali S, Chen C, Rathnasabapathy C and Wang JC: JAK2 mutation in a patient with CLL with coexistent myeloproliferative neoplasm (MPN). Leuk Res. 33:e236–e239. 2009. View Article : Google Scholar : PubMed/NCBI
11	Henry L, Carillo S, Jourdan E, Arnaud A, Brun S and Lavabre-Bertrand T: Association of essential thrombocythemia and chronic lymphocytic leukemia: Absence of the V617F JAK2 mutation in the lymphoid compartment. Am J Hematol. 82:500–501. 2007. View Article : Google Scholar : PubMed/NCBI
12	Hussein K, Brakensiek K, Ballmaier M, Göhring G, Buhr T, Bock O and Kreipe H: B-CLL developing in a patient with PV is not affected by V617F mutation of the Janus kinase 2. Eur J Haematol. 77:539–541. 2006. View Article : Google Scholar : PubMed/NCBI
13	Gaillard JB, Carillo S, Henry L, Jourdan E and Lavabre-Bertrand T: Association of myeloproliferative and lymphoproliferative disorders. Clin Adv Hematol Oncol. 10:756–757. 2012.PubMed/NCBI
14	Tabaczewski P, Nadesan S and Lim SH: Zap-70 positive chronic lymphocytic leukemia co-existing with Jak 2 V671F positive essential thrombocythemia: A common defective stem cell? Leuk Res. 33:854–855. 2009. View Article : Google Scholar : PubMed/NCBI